Jaguar Health, Inc. (JAGX) Earnings Call Transcript
November 17, 2025
Earnings Call Speaker Segments
Thanks so much. I appreciate that intro. Everyone, hello. Good morning. I'm Lisa Conte, and I serve as Founder, President and CEO of Jaguar Health, along with Napo Pharmaceuticals, which we wholly own, and I also hold the Chairman role at our Italian subsidiary, Napo Therapeutics. Before I get into my comments, a quick note: when I say Jaguar or Napo, I'm talking about the same company. Once I wrap up this morning, our CFO, Carol Lizak, will walk you through the financial highlights from Q3 2025. But first, I'm going to jump in ahead of Carol once more, since we have good news: combined net revenue for the third quarter of 2025 came in at roughly $3.1 million across prescription and nonprescription products, license revenue included — that's up about 4% compared with net Q2 2025 revenue of approximately $3 million. I'm also glad to share that 2025 remains the year when Jaguar's major clinical and regulatory catalysts are coming together. We see these catalysts as game-changing when it comes to the worth they deliver for everyone with a stake in the company — patients, and patients matter enormously here, plus shareholders, who also matter a great deal. Put plainly, now that these catalysts have recently been reached, our approach is still to strike business development deals for licensed rights covering development and commercialization of our late-stage health products for both Humans and Animals, with the goal of securing non-dilutive funding for Jaguar. At present, business development talks are underway on three major late-stage initiatives. The initial one concerns our orphan indications for crofelemer in intestinal failure associated with the congenital diarrheal disease called MVID, microvillus inclusion disease. I'm going to use the abbreviation MVID, and for short bowel syndrome, I'll use SBS. This particular program uses crofelemer, but it's not the Mytesi version of crofelemer that we already sell. Here crofelemer is in a separate, new, very concentrated liquid form, one that suits the patient's condition — changed from a lyophilized cake into a liquid. So, what does intestinal failure mean? It's a lifelong, debilitating illness in which patients must get fluids, electrolytes, and nutrients that keep them alive via intravenous delivery. That delivery is made up of what's known as TPN, or total parenteral nutrition, plus extra intravenous fluids, and those two things together are called parenteral support. As you might expect, even just hearing that sounds awful. The people we're discussing cannot take in the essential nutrients they need—things like protein and carbohydrates—so they depend on intravenous feeding to stay alive. For a large share of those with intestinal failure, this means relying on parenteral support as often as seven days each week, and in some cases they remain connected to an IV line for at least 20 hours per day. It goes without saying that this represents a devastating set of circumstances, both from a medical standpoint and in terms of how someone lives day to day. Turning to short bowel syndrome, this condition affects a small number of people—roughly 400 up to 40,000 individuals around the world. For that use, Jaguar has been granted orphan drug status both in the United States and across Europe. Now looking at MVID, meaning intestinal failure tied to MVID, this is an extremely uncommon condition, affecting somewhere between 100 and 200 people worldwide, and here too we have obtained orphan drug designation within the U.S. And Europe. Babies born with this genetic defect face a lethal natural course. They never reach adulthood. Their only chance of survival is immediate treatment with TPN, total parenteral nutrition, as I said, parenteral support, which carries many toxicities, among them liver and kidney toxicity, neurodevelopment delay, and many others that frequently turn life-threatening. Crofelemer has demonstrated a groundbreaking decrease in parenteral support of as much as 37%. This is hugely important, as you can probably imagine, when it comes to reducing how long patients remain on toxic TPN and parenteral support. The finding was presented last week in Chicago at the annual meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, or NASPGHAN, and Dr. Mohamad Miqdady, who serves as primary investigator on this investigator-initiated trial, delivered the data. Why does this matter? Because decreasing reliance on parenteral nutrition and parenteral support has the potential to extend life, save lives, and alter how the disease progresses, and it creates an opportunity for improved quality of life in what is otherwise a devastating medical and disease circumstance for the patient and, honestly, for the entire family and the caregiving team surrounding that child. The fact that there are no approved therapies for MVID makes this result particularly noteworthy, and as far as we're aware, nothing is even being developed for the condition. In addition, data presented at NASPGHAN showed two short bowel syndrome patients who were dependent on parenteral support—parenteral nutrition and parenteral support—and they experienced reductions of about 12% in that support. For the same reason, that result matters just as much, since it offers an opportunity to reduce the toxicity associated with parenteral support. Furthermore, some short bowel syndrome patients can potentially be treated with a growth hormone strategy to grow their short bowel. And as a side note, by the way, growth hormone isn't a standard of care, as it has many side effects of its own. And on top of that, it isn't even feasible in an MVID patient, since MVID patients have fully intact guts. They simply aren't functioning, so there is nothing to grow. But in any case, in short bowel syndrome, about 1/3 of that population are patients whose short bowel stems from surgical reasons and who have adaptation issues during which they cannot receive growth hormone and/or may have a hyper-proliferative circumstance such as cancer and therefore are definitely not candidates for a growth hormone approach. Crofelemer has once more demonstrated proof of concept among an orphan patient group that has no available treatments and nothing being developed. Also, this constitutes a distinct product from Mytesi, sharing the same active ingredient, crofelemer, and it will be brought to market worldwide under a business model linked to, and suited for, rare disease incentives. Now I'll move on to the other central crofelemer development effort of ours, cancer therapy related diarrhea, or CTD, which is intended as a label extension through a supplemental NDA for Mytesi, a product already cleared by the FDA. This program — again, it remains a separate product in its own right, distinct from the <<inaudible>> — and that highly concentrated liquid formulation is also the subject of business development discussions that continue at present. The key regulatory step—a separate Type C meeting with the FDA, scheduled for May 2025—will focus on a quicker path to approval for metastatic breast cancer patients. That approach relies on supporting data for preventing cancer therapy-related diarrhea in breast cancer patients, which comes from the completed Phase III on-target study presented at the San Antonio Breast Cancer Symposium in December 2024. We plan to combine that with anticipated results from a pivotal randomized withdrawal treatment study in metastatic breast cancer patients, expected to start in early 2026. From what we've observed, for a product that truly works, a randomized withdrawal study is the optimal design possible. In this trial design, patients receive the active drug initially, and if they show a response, they're then assigned by chance to either continue on the active drug or switch to a placebo. As a reminder, this trial is using the same dose and formulation that's already approved under the name Mytesi for diarrhea tied to HIV—so the long-term safety profile and the manufacturing regulatory hurdles were obviously dealt with quite some time ago. The two biggest reasons NDAs get rejected are long-term safety—or really any safety concern—and manufacturing. And as I said, with Mytesi, every one of those boxes has already been checked.
One efficacy end point could broaden the label for Mytesi into cancer therapy-related diarrhea through a supplemental NDA, and that cancer therapy-related diarrhea represents a blockbuster chance for patients, obviously, and for the market as well. Roughly 160,000 people in the United States have metastatic breast cancer, and a large share of them remain on targeted therapies that cause diarrhea for the remainder of their lives — therapies that, thankfully, are sometimes turning into 5, 10, 15 years of survival. We have submitted a filing seeking orphan drug designation for the metastatic breast cancer indication. About 40% of patients stop taking their life-saving targeted therapies, and the specific reason is diarrhea; crofelemer now has a chance to help not just with patient quality of life, dignity and comfort — as significant as those supportive care effects are — but also to affect the outcome of their cancer therapy, meaning its successful outcome. Turning now to the Animal Health portion of our business. Our main effort for Canalevia, our prescription drug candidate made of crofelemer — Canalevia is an animal formulation indication that holds FDA conditional approval under the name Canalevia CA-1 for treating chemotherapy-induced diarrhea in dogs. And what we are mainly doing is holding negotiations with prospective partners to work alongside, so as to accomplish three goals running in parallel for the drug: broaden the U.S. indication from chemotherapy-induced diarrhea in dogs to the treatment of general diarrhea in dogs; secure approval in the European Union for Canalevia for general diarrhea in dogs, drawing on an existing Jaguar study that is already in place; and keep availability continuous in the United States of Canalevia for chemotherapy-induced diarrhea in dogs, the use for which it is already approved once more. Strikingly, a cancer patient in the United States who has diarrhea can get crofelemer promoted and prescribed if that patient happens to be a dog — a human, not yet. I am happy to report that Jaguar right now is in discussions with several potential animal health company partners about collaborating to bring Canalevia through regulatory approval and into commercialization for general diarrhea worldwide. This marks our third business development negotiation currently underway, aimed at bringing in nondilutive dollars that acknowledge the contribution to late-stage drug development and risk reduction Jaguar has accomplished with crofelemer across various indications. As for the timeline tied to these activities for intestinal failure, it rests on a Type C meeting — a separate meeting from the cancer meeting we held with the FDA on October 2. We set out a pathway for possible expedited review built on continued results like what we are seeing in the MVID patient, with data potentially fileable by the end of 2026, based literally on a single-digit number of patients given how ultra-rare the disease is and its lethal natural history, and we are also looking next year toward breakthrough designation in the United States and PRIME in Europe — programs that assist in getting products approved in an expedited manner for an ultra-rare disease situation. Regarding diarrhea tied to cancer therapy, our goal is to finish the randomized withdrawal trial by the close of 2026, which would also back a supplemental NDA submission. From the data at the end of 2026, that gives us two possible NDA filings on the Human side. Over in Animal Health, we aim to finalize a partnership in that area very soon. At this point I'll pass things along to Carol, our CFO, so she can walk through the financial highlights for Q3 of 2026. Go ahead, Carol.
Good morning, Lisa, and I appreciate everyone joining our webcast today. I'll start by walking through our financials for Q3 2025. Total net revenue for the third quarter of 2025 came to roughly $3.1 million across prescription and nonprescription products, plus license revenue — that's up about 4% from roughly $3 million in net revenue for the second quarter of 2025, and it matched the approximately $3.1 million in net revenue from the third quarter of 2024. Mytesi prescription volume rose roughly 0.9% in Q3 2025 compared with this year's second quarter, while Mytesi prescription volume for the third quarter of 2025 fell 3.6% relative to the volume seen in last year's third quarter. Prescription volume isn't the same as invoiced sales volume — it reflects, among other things, differing purchasing patterns at specialty pharmacies within the closed network as they handle their inventory levels. Loss from operations improved by $24,000, going from $7.2 million in the quarter that ended September 30, 2024, to $7.3 million for the same period this year. Non-GAAP recurring EBITDA for the third quarters of 2025 and 2024 showed net losses of $8.9 million and $9.2 million, respectively. Net loss attributable to common shareholders improved by $352,000, from $9.9 million in the quarter ended September 30, 2024, down to $9.5 million in the same period of 2025; that wraps up my summary of the top-line financials for Q3 2025. I'll now turn things back over to Lisa.
Appreciate that, Carol. Alright, everyone in the Jaguar, Napo, and Napo Therapeutics family, we're still completely energized and thrilled about the several near-term catalysts we anticipate for crofelemer across the company — every one of which we see as meaningfully value-enhancing and possibly transformative for patients and, as I said, for all stakeholders, our shareholders included. Drug development plays out over the long haul, and these catalysts mark where key potential inflection points converge across our major programs, efforts we've invested in for years. We also anticipate that these catalysts will produce major collaborations, business development and licensing agreements, plus the chance to bring in nondilutive dollars that help move these late-stage products and programs toward regulatory approval and reimbursed patient access. That wraps up our webcast for today. Thanks to each of you for joining. Enjoy a wonderful Thanksgiving and holiday with your families. We'll reconnect next quarter. Thank you.
For developers and AI pipelines
Programmatic access to Jaguar Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.